As if it wasn't obvious by the endless fountain of ebullient headlines, Ozempic is the gift that keeps on giving for Novo Nordisk (NYSE: NVO) and its investors. Ozempic's active ingredient, semaglutide, received initial approval from the FDA for treating type 2 diabetes. It's now also approved for sale under different trade names like Wegovy to treat obesity, and there's plenty of ongoing research that indicates that it could be helpful for a smattering of other conditions as well.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles